

The United States vs. Other Countries: Availability of Cancer Medicines Varies

The proposed International Pricing Index Model would set U.S. prices for medicines covered under Medicare Part B based on the pricing policies of 14 foreign governments – many of which set prices artificially low, resulting in severe access restrictions for patients.

	New Cancer Medicines Available	Delay in Availability of Cancer Medicines
 Greece	8%	32 months
 Czech Republic	40%	25 months
 Ireland	45%	22 months
 Japan	47%	23 months
 Belgium	53%	26 months
 Canada	56%	13 months
 Italy	57%	20 months
 Denmark	57%	11 months
 Finland	60%	14 months
 Netherlands	61%	9 months
 France	64%	20 months
 United Kingdom	71%	11 months
 Austria	73%	12 months
 Germany	75%	11 months
 United States	96%	0-3 months

Source: PhRMA analysis of IQVIA Analytics Link and FDA, EMA and PMDA data. November 2018.

Note: New cancer medicines refers to those first launched globally between January 2011 and June 2018. Average delay represents the time in months between global first launch and availability in a given country.